Japan Intranasal Drug And Vaccine Delivery Market Size & Outlook
Related Markets
Japan intranasal drug and vaccine delivery market highlights
- The Japan intranasal drug and vaccine delivery market generated a revenue of USD 2,883.6 million in 2023 and is expected to reach USD 4,734.3 million by 2030.
- The Japan market is expected to grow at a CAGR of 7.3% from 2024 to 2030.
- In terms of segment, liquid delivery device was the largest revenue generating product in 2023.
- Liquid Delivery Device is the most lucrative product segment registering the fastest growth during the forecast period.
Intranasal drug and vaccine delivery market data book summary
| Market revenue in 2023 | USD 2,883.6 million |
| Market revenue in 2030 | USD 4,734.3 million |
| Growth rate | 7.3% (CAGR from 2023 to 2030) |
| Largest segment | Liquid delivery device |
| Fastest growing segment | Liquid Delivery Device |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Powder delivery device, Liquid Delivery Device, Pressurized Metered Dose Inhaler |
| Key market players worldwide | GSK PLC ADR, Teva Pharmaceutical Industries Ltd, AptarGroup Inc, UCB SA, Teleflex Inc, 3M Co, OptiNose Inc, Bespak, Intersect ENT |
Other key industry trends
- In terms of revenue, Japan accounted for 4.4% of the global intranasal drug and vaccine delivery market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China intranasal drug and vaccine delivery market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 5,992.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intranasal Drug And Vaccine Delivery Market Scope
Intranasal Drug And Vaccine Delivery Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Intersect ENT | View profile | 251-500 | Menlo Park, California, United States, North America | http://www.intersectent.com |
| Bespak | View profile | 501-1000 | Lynn, Norfolk, United Kingdom, Europe | http://www.bespak.com |
| OptiNose Inc | View profile | 132 | 1020 Stony Hill Road, Suite 300, Yardley, PA, United States, 19067 | https://www.optinose.com |
| Teleflex Inc | View profile | 14500 | 550 East Swedesford Road, Suite 400, Wayne, PA, United States, 19087 | https://www.teleflex.com |
| UCB SA | View profile | 9083 | Allee de la Recherche, 60, Brussels, Belgium, B-1070 | https://www.ucb.com |
| AptarGroup Inc | View profile | 13800 | 265 Exchange Drive, Suite 301, Crystal Lake, IL, United States, 60014 | https://www.aptar.com |
| GSK PLC ADR | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| 3M Co | View profile | 85000 | 3M Center, St. Paul, MN, United States, 55144 | https://www.3m.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
Japan intranasal drug and vaccine delivery market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intranasal drug and vaccine delivery market will help companies and investors design strategic landscapes.
Liquid delivery device was the largest segment with a revenue share of 43.36% in 2023. Horizon Databook has segmented the Japan intranasal drug and vaccine delivery market based on powder delivery device, liquid delivery device, pressurized metered dose inhaler covering the revenue growth of each sub-segment from 2018 to 2030.
The intranasal drug and vaccine delivery market in Japan held 21.1% of share in 2021 owing to rising R&D efforts by key players operating in the market to deliver novel products. Japan is a member of the OECD countries and an important member of the Asia Pacific trade block.
Increasing various government initiatives regarding technological advancement and balancing the effective regulatory compliance requirement are also among contributing factors expected to boost regional growth. Thus, the abovementioned factors are further expected to boost market growth.
Increasing awareness about nasal drug delivery systems, especially for allergic rhinitis, is one of the key factors driving the market. For instance, a specific Japanese guideline for allergic rhinitis was prepared in 2017 to understand drug delivery and its proper application for treatment.
Reasons to subscribe to Japan intranasal drug and vaccine delivery market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan intranasal drug and vaccine delivery market databook
-
Our clientele includes a mix of intranasal drug and vaccine delivery market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan intranasal drug and vaccine delivery market , including forecasts for subscribers. This country databook contains high-level insights into Japan intranasal drug and vaccine delivery market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan intranasal drug and vaccine delivery market size, by product, 2018-2030 (US$M)
Japan Intranasal Drug And Vaccine Delivery Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
